Engineered immune cells take aim at childhood leukemia
NCT ID NCT05010564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukemia cells carrying three markers: CD19, CD20, and CD22. After a short course of chemotherapy, the modified T cells are infused back into the patient. The main goal is to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TRICAR-ALL T cells (genetically modified T cells targeting CD19, CD20, and CD22) plus lymphodepletion chemotherapy (fludarabine and cyclophosphamide)
- What this could lead to
- If successful, this could offer a new treatment option for children and young adults with B-cell acute lymphoblastic leukemia that has returned or not responded to standard therapy.
- What could go wrong
- This is an early Phase 1 trial with only 38 participants, so it is primarily testing safety and dosing. The treatment may cause serious side effects like cytokine release syndrome, and it is not yet proven to work or be widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can donor immune cells be engineered to fight blood cancer?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests